{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:45:59Z","timestamp":1761237959521},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T00:00:00Z","timestamp":1355788800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0051771","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T22:10:59Z","timestamp":1355868659000},"page":"e51771","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia"],"prefix":"10.1371","volume":"7","author":[{"given":"Onkar","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keegan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Chuah Thuan","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balram","family":"Chowbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"RA Larson","year":"2008","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"TP Hughes","year":"2010","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"A Haouala","year":"2011","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"NP van Erp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"DL White","year":"2007","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"S Picard","year":"2007","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000336244","article-title":"Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients","volume":"127","author":"JS Zhong","year":"2012","journal-title":"Acta Haematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"N Takahashi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3109\/10428194.2011.563885","article-title":"Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia","volume":"52","author":"SK Sohn","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, <etal>et al<\/etal>.. (2012) Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol.","DOI":"10.1002\/hon.2005"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","volume":"34","author":"A Awidi","year":"2010","journal-title":"Leuk Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"DL Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"QB Li","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00277-011-1394-x","article-title":"Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting","volume":"91","author":"E Faber","year":"2012","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"JE Cortes","year":"2009","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"J Thomas","year":"2004","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Crossman LC, Druker BJ, Deininger MWN, Pirmohamed M, Wang L, <etal>et al<\/etal>.. (2005) hOCT 1 and resistance to imatinib. Blood 106: 1133\u20134; author reply 1134.","DOI":"10.1182\/blood-2005-02-0694"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000336610","article-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","volume":"127","author":"L Nardinelli","year":"2012","journal-title":"Acta Haematol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"WW Zhang","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"DHD Kim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2010.86","article-title":"hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia","volume":"24","author":"A Bazeos","year":"2010","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"M Maffioli","year":"2011","journal-title":"Leuk Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"DL White","year":"2010","journal-title":"Leukemia"},{"key":"ref28","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Y Yamakawa","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hughes T (2006) ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program 211\u2013218.","DOI":"10.1182\/asheducation-2006.1.211"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","article-title":"Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients","volume":"13","author":"B Chowbay","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00228-003-0594-2","article-title":"CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations","volume":"59","author":"C Balram","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","article-title":"Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C&gt;A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients","volume":"98","author":"SR Jada","year":"2007","journal-title":"Cancer Sci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-08-0411","article-title":"PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients","volume":"14","author":"E Sandanaraj","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2125.2004.02330.x","article-title":"Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer","volume":"59","author":"Q Zhou","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","article-title":"Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples","volume":"804","author":"T Velpandian","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/bmc.816","article-title":"Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography","volume":"21","author":"RL Oostendorp","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e7013","DOI":"10.1371\/journal.pone.0007013","article-title":"Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk","volume":"4","author":"S Karami","year":"2009","journal-title":"PloS one"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/338688","article-title":"Score tests for association between traits and haplotypes when linkage phase is ambiguous","volume":"70","author":"DJ Schaid","year":"2002","journal-title":"Am J Hum Genet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ng1669","article-title":"Efficiency and power in genetic association studies","volume":"37","author":"PIW de Bakker","year":"2005","journal-title":"Nat Genet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/bioinformatics\/btl580","article-title":"WHAP: haplotype-based association analysis","volume":"23","author":"S Purcell","year":"2007","journal-title":"Bioinformatics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e13967","DOI":"10.1371\/journal.pone.0013967","article-title":"Investigation of a genome wide association signal for obesity: synthetic association and haplotype analyses at the melanocortin 4 receptor gene locus","volume":"5","author":"A Scherag","year":"2010","journal-title":"PloS one"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Y Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.pharmtox.38.1.431","article-title":"Role of organic cation transporters in drug absorption and elimination","volume":"38","author":"L Zhang","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1124\/jpet.110.170159","article-title":"Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function","volume":"335","author":"L Chen","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Y Shu","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Y Shu","year":"2007","journal-title":"J Clin Invest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"H Gurney","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"ER Gardner","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"S Dulucq","year":"2008","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"S Hu","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0051771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T05:53:27Z","timestamp":1562478807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0051771"}},"subtitle":[],"editor":[{"given":"Wei Ning","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,18]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0051771","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,18]]}}}